Eli Lilly Says LIBRETTO-531 Study Evaluating Retevmo Meets Primary Endpoint

Eli Lilly Q2 Results Top Estimates; Boosts FY24 Outlook

Drugmaker Eli Lilly reported Thursday a net profit for the second quarter that surged 68 percent from last year, reflecting strong Mounjaro, Zepbound and Verzenio sales as well as higher realized prices. Both adjusted earnings per share and revenues topped analysts' expectations. The company also raised its guidance for the full-year 2024.

RTTNews | 776 hari yang lalu

Eli Lilly Again Boosts FY24 Outlook - Update

While reporting financial results for the second quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2024, primarily driven by the strong performance of Mounjaro and Zepbound, as well as the company's non-incretin medicines.

RTTNews | 776 hari yang lalu

Eli Lilly Collaborates With OpenAI To Use Generative AI To Invent Novel Antimicrobials

Eli Lilly and Co. (LLY) announced Tuesday a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.

RTTNews | 820 hari yang lalu

Eli Lilly CFO Anat Ashkenazi Resigns

Eli Lilly and Co. (LLY) announced Wednesday that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry.

RTTNews | 840 hari yang lalu

Lilly Says Phase 3 Trials Of Once-weekly Insulin In Type 2 Diabetes Meets Primary Endpoint

Eli Lilly and Co. (LLY) announced Thursday positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using insulin for the first time (insulin naïve) and those who require multiple daily insulin injections.

RTTNews | 860 hari yang lalu

Eli Lilly Boosts FY24 Outlook - Update

While reporting financial results for the first quarter on Tuesday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2024, primarily driven by the strong performance of Mounjaro and Zepbound and greater visibility into the company's production expansion for the remainder of the year.

RTTNews | 876 hari yang lalu

Eli Lilly Q4 Results Top Estimates

Drugmaker Eli Lilly reported Tuesday a profit for the fourth quarter that grew 13 percent from last year, reflecting strong Mounjaro sales and higher realized prices. Both adjusted earnings per share and revenues topped analysts' expectations. The company also provided strong revenue guidance for the full-year 2024.

RTTNews | 960 hari yang lalu

Eli Lilly Guides FY24 Revenues Above Estimates - Update

While reporting financial results for the fourth quarter on Tuesday, drugmaker Eli Lilly and Co. (LLY) initiated its earnings, adjusted earnings and revenue guidance for the full-year 2024.

RTTNews | 960 hari yang lalu

EURUSD	1.13855	GBPUSD	1.32429
USDJPY	158.316	USDCAD	1.40979